<div id="readability-page-1"><p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $10.01, for a total transaction of $13,463.45. Following the completion of the sale, the insider owned 132,635 shares of the company's stock, valued at $1,327,676.35. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p><div><p><span></span><span>Get <strong>Cullinan Therapeutics</strong> alerts:</span></p></div><p>Jennifer Michaelson also recently made the following trade(s): </p><ul><li>On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total transaction of $28,023.66. </li><li>On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $11,840.50. </li><li>On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.38, for a total transaction of $26,592.24. </li><li>On Monday, November 24th, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total transaction of $49,200.00. </li></ul><h2>Cullinan Therapeutics Stock Performance</h2><p>Shares of NASDAQ CGEM traded up $0.66 during mid-day trading on Monday, hitting $10.34. The stock had a trading volume of 1,417,011 shares, compared to its average volume of 661,685. The firm has a market cap of $610.85 million, a PE ratio of -3.12 and a beta of -0.10. The company has a 50 day moving average of $9.35 and a two-hundred day moving average of $8.11. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $13.33. </p><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.18.  Equities research analysts predict that  Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities analysts have issued reports on CGEM shares. Zacks Research raised shares of Cullinan Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, September 16th. New Street Research  set a $26.00 target price on shares of Cullinan Therapeutics in a report on Thursday, November 20th. HC Wainwright boosted their target price on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 20th. Wall Street Zen raised Cullinan Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Cullinan Therapeutics in a research note on Monday, December 8th. Six research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.29.</p><p><b>Get Our Latest Report on Cullinan Therapeutics</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently modified their holdings of CGEM. Vanguard Group Inc. grew its position in shares of  Cullinan Therapeutics by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 3,039,731 shares of the company's stock valued at $23,011,000 after acquiring an additional 103,504 shares during the period.  Nuveen LLC acquired a new position in  Cullinan Therapeutics in the 1st quarter worth about $1,423,000.  Russell Investments Group Ltd. purchased a new position in  Cullinan Therapeutics during the first quarter worth approximately $222,000.  American Century Companies Inc. grew its holdings in  Cullinan Therapeutics by 11.9% in the first quarter. American Century Companies Inc. now owns 112,670 shares of the company's stock valued at $853,000 after purchasing an additional 11,949 shares during the period.  Finally, Brooklyn Investment Group acquired a new stake in  Cullinan Therapeutics in the first quarter valued at approximately $34,000. Institutional investors and hedge funds own  86.31% of the company's stock. </p><h2>About Cullinan Therapeutics</h2> (Get Free Report)<p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Cullinan Therapeutics</li><li>The Fed Pivot Signal Smart Money’s Been Waiting For</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>Do not delete, read immediately</li><li>How Long Will $1M Last in Retirement?</li><li>Protect Your Bank Account with THESE 4 Simple Steps</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGEM

<p>Jennifer Michaelson, an insider at Cullinan Therapeutics, sold 1,345 shares for $13,463.45, reducing her position by 1%. The sale was disclosed to the SEC. Michaelson has made several other sales recently, totaling thousands of shares. Cullinan's stock performance shows a recent increase, with analysts providing mixed ratings and target prices. Institutional investors have adjusted their holdings, with some increasing their positions in the company.</p>

Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock